Form 8-K - Current report:
SEC Accession No. 0001493152-22-021569
Filing Date
2022-08-08
Accepted
2022-08-08 09:10:42
Documents
15
Period of Report
2022-08-08
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38769
2 ex99-1.htm EX-99.1 81709
3 ex99-1_1.jpg GRAPHIC 5687
4 form8k_001.jpg GRAPHIC 5687
  Complete submission text file 0001493152-22-021569.txt   325824

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE lpcn-20220808.xsd EX-101.SCH 2959
6 XBRL LABEL FILE lpcn-20220808_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE lpcn-20220808_pre.xml EX-101.PRE 22359
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3605
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36357 | Film No.: 221142774
SIC: 2834 Pharmaceutical Preparations